NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the
“
Company” or “
NurExone”), a
biopharmaceutical company developing biologically-guided exosome
therapy for patients with traumatic spinal cord injuries, is
pleased to announce that it has closed the second and final tranche
(the “
Second Tranche”) of its previously announced
non-brokered private placement (the “
Private
Placement”). An aggregate of 750,000 units of the Company
(each a “
Unit”) were issued and sold under the
Second Tranche at a price of CAD$0.275 per Unit for aggregate
proceeds of CAD$206,250. In the aggregate, the Company issued and
sold 5,394,548 Units at a price of CAD$0.275 per Unit for aggregate
proceeds of CAD$1,483,500.70 under the Private Placement.
“I am pleased with the outcome of our Private
Placement and on behalf of NurExone’s team, I would like to thank
our investors and shareholders for the support and trust in the
Company and its team”, said Dr. Lior Shaltiel, CEO of NurExone.
“The Company intends to use the proceeds of the
Private Placement for progressing the development activities on the
Company’s assets, working capital, and for general corporate
purposes”, said Eran Ovadya, CFO of NurExone.
Each Unit consists of (i) one common share in
the capital of the Company (each, a “Common
Share”); (ii) one-half of one class A Common Share
purchase warrant (each whole class A Common Share purchase warrant,
a “Class A Warrant”); and (iii) one-half of one
class B Common Share purchase warrant (each whole class B Common
Share warrant, a “Class B Warrant” and
collectively each whole Class A Warrant and each whole Class B
Warrant, a “Warrant”). Each Class A Warrant
entitles the holder thereof to purchase one Common Share at a price
of CAD$0.34 per Common Share for a period of 24 months from the
closing of the Second Tranche and each whole Class B Warrant
entitles the holder thereof to purchase one Common Share at a price
of CAD$0.48 per Common Share for a period of 36 months from the
closing of the Second Tranche.
The Warrants are subject to accelerated
expiration whereby if the daily volume weighted average trading
price of the Common Shares on the TSX Venture Exchange
(“TSXV”) for any period of 20 consecutive trading
days equals or exceeds CAD$0.69 in respect of the Class A Warrants
or CAD$0.83 in respect of the Class B Warrants, the Company may,
upon providing written notice to the holders of the Class A
Warrants or Class B Warrants, as applicable (the
“Acceleration Notice”), accelerate the expiry date
of the respective Class A Warrants or Class B Warrants to the date
that is 30 days following the date of the Acceleration Notice. If
the Warrants are not exercised by the applicable accelerated expiry
dates, the Warrants will expire and be of no further force or
effect.
All securities issued under the first and Second
Tranche are subject to a statutory hold period of four months and
one day from the closing of the Second Tranche. The Private
Placement is subject to final approval of the TSXV.
This news release does not constitute an offer
to sell or a solicitation of an offer to buy any of the securities
described in this news release in the United States. Such
securities have not been, and will not be, registered under the
United States Securities Act of 1933, as amended (the “U.S.
Securities Act”), or any state securities laws, and,
accordingly, may not be offered or sold within the United States,
or to or for the account or benefit of persons in the United States
or “U.S. Persons”, as such term is defined in Regulation S
promulgated under the U.S. Securities Act, unless registered under
the U.S. Securities Act and applicable state securities laws or
pursuant to an exemption from such registration requirements.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed
pharmaceutical company that is developing a platform for
biologically-guided ExoTherapy to be delivered, non-invasively, to
patients who suffered traumatic spinal cord injuries. ExoTherapy
was conceptually demonstrated in animal studies at the Technion,
Israel Institute of Technology. NurExone is translating the
treatment to humans, and the company holds an exclusive worldwide
license from the Technion and Tel Aviv University for the
development and commercialization of the technology.
For additional information, please visit www.nurexone.com
or follow NurExone on LinkedIn, Twitter, Facebook,
or YouTube.For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and DirectorPhone:
+972-52-4803034Email: info@nurexone.com
Investor RelationsPhone: +1 905-347-5569Email:
IR@nurexone.com
FORWARD-LOOKING STATEMENTS
This press release contains certain
“forward-looking statements”, that reflect the Company’s current
expectations and projections about its future results. Wherever
possible, words such as “may”, “will”, “should”, “could”, “expect”,
“plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or
“potential” or the negative or other variations of these words, or
similar words or phrases, have been used to identify these
forward-looking statements. Forward-looking statements in this
press release include, but are not limited to, statements relating
to the use of proceeds of the Private Placement and the receipt of
final approval of the TSXV of the Private Placement. These
statements reflect management’s current beliefs and are based on
information currently available to management as at the date
hereof.
In developing the forward-looking statements in
this press release, we have applied several material assumptions,
including our ability to attract investors on the terms under the
Private Placement; the general business and economic conditions of
the industries and countries in which we operate; the market
conditions; inflation will remain stable; and that the results of
our studies reflect results that can be extrapolated.
Forward-looking statements involve significant
risk, uncertainties and assumptions. Many factors could cause
actual results, performance or achievements to differ materially
from the results discussed or implied in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks related to the Company’s early stage of
development, lack of revenues to date, government regulation,
market acceptance for its products, rapid technological change,
dependence on key personnel, protection of the Company’s
intellectual property, dependence on the Company’s strategic
partners and the risks discussed under the heading “Risk Factors”
on pages 29 to 36 of the Company’s Annual Information Form dated
March 30, 2023, a copy of which is available under the Company’s
SEDAR+ profile at www.sedarplus.ca. These factors should be
considered carefully and readers should not place undue reliance on
the forward-looking statements. Although the forward-looking
statements contained in this press release are based upon what
management believes to be reasonable assumptions, the Company
cannot assure readers that actual results will be consistent with
these forward-looking statements. These forward-looking statements
are made as of the date of this press release, and the Company
assumes no obligation to update or revise them to reflect new
events or circumstances, except as required by law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024